Innova Captab Limited announced a landmark financial performance for the fiscal year ending March 31, 2026. The company reported a robust annual revenue of INR 1,630 crores, marking a 31% year-on-year growth. Driven by the successful ramp-up of the Jammu facility and a strong product portfolio across both CDMO and Branded Generics businesses, the company remains focused on driving sustained margin expansion and long-term shareholder value through strategic capacity enhancements.
Financial Performance Overview
The fiscal year 2026 proved to be a defining period for Innova Captab Limited, characterized by the company’s highest-ever annual performance. Consolidated revenue reached INR 1,630 crores, representing a 31% growth over the previous year. Specifically, for the fourth quarter (Jan-Mar 2026), revenue stood at INR 447.8 crores, a substantial 42% year-on-year increase, bolstered by strong demand in all business segments.
Segment Growth and Operational Success
The company’s growth was driven by its two primary business areas: CDMO and Branded Generics. The CDMO business reported annual revenue of INR 1,133 crores, reflecting a 24% growth, while the Branded Generics business delivered a robust 51% growth with revenues of INR 497 crores.
A central highlight of the year was the successful operational ramp-up of the Jammu facility. This facility achieved INR 300 crores in revenue during its first full year of operations, and management expects it to reach EBITDA-positive status in the coming quarters, contributing significantly to future operating leverage and profitability.
Strategic Outlook and Future Roadmap
Looking ahead, the company is committed to maintaining a 20% plus revenue growth. Management emphasized a disciplined approach to capital allocation, including potential capex for a new Baddi plant to expand capacity for the general portfolio. With new regulatory milestones achieved, including UK-MHRA approval for the cephalosporin facility and PIC/S certification for the Jammu blocks, the company is well-positioned to strengthen its footprint in regulated international markets.
Profitability is expected to outpace revenue growth as the Jammu facility reaches optimal utilization, with fixed costs already largely absorbed into the current base. The company remains focused on R&D, product portfolio expansion, and deepening customer relationships to sustain its growth momentum.
Source: BSE
